Mydecine Innovations Group Archives - Green Market Report

StaffOctober 19, 2020
shutterstock_431001775-scaled.jpg?fit=1200%2C797&ssl=1

3min14360

Mydecine Innovations Group, Inc, (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) announced the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.

Among the factors considered by the Company in pursuing the dual listing, Mydecine™ noted that the LSE currently has a limited number of sizable psychedelics-focused biotech companies. Mydecine, as a contributing member to Drug Science UK, the only completely independent, science-led drugs charity, believes the LSE listing will provide UK and European investors with greater, more local exposure to a new high-quality investment choice of a business type not currently available on the Exchange.

Highlights

Mydecine’s appointment of Boustead enables it to commence the LSE listing process and act on its intention for the Company’s common shares to trade on the Main Market in the next few months. In addition to its current listings in Canada, the United States, and Germany, the Company believes that a listing on the LSE makes it well-positioned to bring European investors into the Company’s share register.

The LSE listing is expected to provide all investors access and exposure to:

  • European Investor base in what the Company believes are Psychedelic-friendly countries such as the Netherlands, United Kingdom, Austria, and Portugal, to name a few
  • Support early and late-phase clinical trials
  • Expansion of the Company’s telehealth platform; Mindleap Health
  • Further development of extensive IP portfolio
  • Furthering the development of novel types of psilocybin-based medicine and unique formulations

Josh Bartch, CEO & Chairman of Mydecine Innovations Group, commented, “The Board of Directors has met a number of times deciding the best route and venue for the new listing of the Company’s securities, adding to our focus on shareholder value. We decided the LSE represented the best stock exchange for our investors, shareholders, and the ongoing growth of the Company. Additionally, it provides a great platform to measurably advance our investor reach within the European investor community. A LSE Listing offers a number of opportunities to fast-track further potential listings to exchanges such as NASDAQ or NYSE. Mydecine Innovations Group has a global reach through the Company’s various planned clinical trials, research facilities, partners and scientific advisors, some of which are located directly in the UK.”


William SumnerOctober 7, 2020
900x500.jpg?fit=900%2C500&ssl=1

6min20410

Psychedelic drugs like psilocybin are a game changer in the world of mental health sciences. There is a growing body of evidence that suggests psilocybin has the potential to help treat anxiety, depression, and post-traumatic stress disorder (PTSD). As scientific interest in psilocybin grows, so too does the attention of investors; many of whom cannot help but see the market similarities between psychedelics, pharmaceuticals, and the cannabis industries.

Indeed, the functional non-psychedelic and gourmet mushroom markets as a whole is poised for explosive growth over the next few years. By 2024 the market is expected to grow to $34.3 billion in sales according to ResearchAndMarkets.com. Recognizing the huge opportunities in these other fungi markets, dozens of companies have sprung up hoping to cash in on the psychedelic mushroom space, like Compass Pathways (NASDAQ: CMPS).

As one of the more high profile companies investigating psilocybin-based therapies, Compass has been enjoying the investor spotlight for the last several months, especially after recently announcing an upsized IPO of more than $127 million. With high profile backers like PayPal billionaire Peter Thiel, Compass has become the company du jour of the psychedelic space, but regulatory uncertainty and issues of scaling still haunt the company’s path to market.

As evidenced by the decades-long disconnect between state and federal cannabis laws, both lawmakers and regulators are slow to embrace substances that carry the social stigma of the War on Drugs, even when there is a large body of evidence suggesting therapeutic potential.

Even if Compass is able to bring a substance to market, it will be subject to heavy restrictions and a long scheduling process, which will significantly stymie any market rollout. In their IPO filing, the company admits as much.

“In addition, the scheduling process may take significantly longer than the 90-day deadline set forth in the CSA, thereby delaying the launch of our investigational COMP360 psilocybin therapy in the United States,” reads the filing.

Further, standing in the way of Compass’ dreams of market primacy is the issue of scaling. The company’s primary source of psilocybin comes from laboratory synthesis, which is prohibitively expensive. Due to the high cost of synthetic psilocybin production, Compass charges their customers anywhere between $7,000-$10,000 USD per gram, averaging out to around $13.20 per milligram.

In comparison, whole-mushroom extraction is significantly cheaper, costing around $0.76 per gram to extract psilocybin, assuming the source of the mushrooms are from a black market dealer. Now, if you can legally produce your own mushrooms, the costs only continues to decline.

Currently, the only company in the world that can legally produce pharmaceutical-grade psilocybin from whole-mushroom extraction is Mydecine Innovations Group (CSE: MYCO). Equipped with a Health Canada Schedule 1 Controlled Drugs and Substances Dealer’s Licence, Mydecine can not only produce whole-mushroom psilocybin extractions, but they can also transfer, sell, and export the substance as well. 

While Compass seems to be mired in regulatory uncertainty south of the Canadian border, Mydecine is quietly conducting, in collaboration with the Dutch Royal Army, the world’s first clinical trials into the efficacy of psilocybin in treating Post-Traumatic Stress Disorder.  Leading these efforts is a science team with a surprisingly deep bench of experts, including a seven-time Nobel Prize nominee and the former chair of the NATO research group on military mental health training.

Though Compass may have a head start, Mydecine has a much clearer path to market; due in no small part to the lack of regulatory uncertainty surrounding Mydecine’s efforts and the company’s ability to produce psilocybin at significantly lower prices. With a solid foundation moving forward, Mydecine seems poised for growth. The question is, will investors take notice?

 


StaffSeptember 24, 2020
mindleap.jpg?fit=300%2C300&ssl=1

5min13711

Mindleap Health, a subsidiary of Mydecine Innovations Group Inc. (OTC:MYCOF) has launched a digital health platform that combines telehealth with mood, emotion, and habit tracking. Starting with psychedelic integration, the Mindleap platform will bring mental health specialists online, enabling a new era of digital mental health and wellness. The company said that later this year it will add other types of mental health specialists such as addiction and holistic wellness specialists.

Simon Abou-Antoun Mindleap Chief Technology officer said, “Mindleap was designed with trust as our number one priority. Our platform is fully secure and all data is encrypted in-transit and at-rest and we are committed to each individual’s right to full privacy and confidentiality when they use our platform.”

The Mindleap platform is available for download for free on both the IOS and Google Play stores. Potential patients can browse vetted and experienced specialists and easily schedule appointments and purchase mental health services. Specialists on Mindleap benefit from the platform’s full freedom to manage their virtual practice on their terms setting their own prices, choosing the hours they work each week (with no minimums or maximums). Mindleap says its specialists are able to offer more personalized support all while providing end-users with the tools needed to track their progress and take control of their mental health.

The Mindleap platform said it will provide a comprehensive space for users to actively engage with specialists starting with aftercare for therapeutic psychedelic use.

Psychedelic Aftercare 

The company has noted that over the past decade, a growing body of research published by leading academic institutions such as Imperial College of London, Yale University, and Johns Hopkins University has demonstrated that psychedelic medicines like MDMA, psilocybin (the active compound ingredient found in magic mushrooms), MDMA, and ketamine can be used as effective and safe treatments to treat a variety of mental health conditions, much better than current pharmacological treatments and therapies. In tandem with this breakthrough knowledge, a series of educational programs have emerged to educate mental health and wellness specialists on how to administer psychedelic medicines in guided therapeutic sessions, as well as to provide care after a psychedelic experience.

Integration specialists help clients through a systematic process that can turn their psychedelic experience into something practical – this can include making sense of unique images or ideas that came to mind during a psychedelic experience, as well as setting new goals, habits and behaviors that can help to improve a person’s life. This process is called integration or aftercare and is an important part of using psychedelics for therapeutic purposes and personal growth.

Mindleap says it does not encourage people to spend time on their phones while taking psychedelic substances, and does not facilitate psychedelic use via the platform, but acknowledges a need for people to connect with trained professionals who can help them discuss and understand their individual psychedelic experiences.

Privacy Concerns

Mindleap’s software development team has built the platform to meet all HIPAA guidelines by implementing secure electronic access to health data and remains in compliance with privacy regulations and best practices. Mindleap said it has strict policies around how data is handled and stored; all data is encrypted in-transit and at-rest, and specialists are not permitted to save their clients’ data – they can only view it temporarily while the user chooses to share it during a video call.


StaffAugust 18, 2020
shutterstock_1789366847-scaled.jpg?fit=1200%2C789&ssl=1

4min30570

Under the coverage of a Health Canada Schedule 1 Controlled Drugs and Substances Dealer’s License, Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine™” or the “Company”) announced that it is the first organization to exercise its cGMP capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin, naturally derived from whole-mushroom extraction.

Mydecine™ has the full range of capabilities to extract fungi’s natural psychedelic compounds, such as psilocybin and psilocin from certain species of fruiting body mushrooms all the way through to distribution. Mydecine™ also has the ability to conduct the most advanced techniques to produce purified pharmaceutical-grade extract, then legally export its finished byproducts to its various research partners throughout the world, including but not limited to the Imperial College of London and Johns Hopkins University.

The Company is also capable of supporting commercial research institutions with product donations, including charitable contributions to provide its purified extracts and formulations to end-of-life distressed patients. The announcement comes on the heels of a recent landmark decision by Health Canada to permit four terminally ill patients to consume psilocybin mushrooms to ease their distress. This historic decision establishes a precedent that will pave the way for a wider adoption of psilocybin-based therapies.

“Mydecine’s breakthrough to legally supply naturally-sourced psilocybin within our spore-to-sale™ process will be a major advancement for mental therapeutics, due to the fact that these unique psychedelic compounds are both safe and effective for afflictions, such as depression, anxiety, and PTSD,” quoted Damon Michaels, COO and Co-Founder of Mydecine™.

There is still debate as to which is more successful in psychedelic-based treatments between naturally derived psilocybin or the use of a synthetic form. Given Mydecine’s full legal ability to access both types of active compounds, the Company is poised to internally answer that question as well as aid various qualified groups also conducting this type of research. In theory, there are a plethora of added benefits in regard to the entourage effect of naturally-sourced psilocybin versus the synthetic route. Additionally, Mydecine™ is developing a number of unique API’s from their naturally-sourced cGMP psychedelic extracts. Mydecine™ will also be conducting R&D to produce novel proprietary formulations by synergizing psychedelic fungi compounds with other various API’s; Mydecine™ will then attach their formulations to their exclusive delivery mechanisms. Mydecine™ plans to utilize these psychedelic medicinal formulations in various clinical environments around the world in aspiration to better the lives of many.

The Company notes that although several international companies and research institutions are permitted to utilize synthesized psilocybin, the process is extremely challenging and cost prohibitive with a single gram having the price tag of thousands of dollars. Being able to legally extract psilocybin from its natural source, Mydecine™ will hope to reduce these significant costs and improve the scalability of world-class research initiatives and novel therapies.

CEO and Director of Mydecine™, Joshua Bartch stated, “We are extremely grateful to have the ability to provide cGMP psychedelic API’s to qualified organizations, research partners, nonprofits, and clinical groups throughout the globe. We believe the reason current psilocybin-based research initiatives come with a very high cost using inefficiently produced synthetic psilocybin is simply due to a lack of capabilities and legal restraints. Mydecine’s legal capabilities through the dealer’s license will incorporate our range of abilities, which will be valuable for naturally-sourced medicine paired with new-age technology. We believe our achievement is the first-of-its-kind.”


AxisWireAugust 18, 2020
logo_mydecine-2.png?fit=850%2C531&ssl=1

9min78760

Being Facilitated Under a Schedule 1 Health Canada Dealer’s License

DENVER, Colorado, USA, August 18, 2020 /AxisWire/ Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine™” or the “Company”) is pleased to announce it is the first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin, naturally derived from whole-mushroom extraction.

Under the coverage of a Health Canada Schedule 1 Controlled Drugs and Substances Dealer’s License, Mydecine™ has the full range of capabilities to extract fungi’s natural psychedelic compounds, such as psilocybin and psilocin from certain species of fruiting body mushrooms all the way through to distribution. Mydecine™ also has the ability to conduct the most advanced techniques to produce purified pharmaceutical-grade extract, then legally export its finished byproducts to its various research partners throughout the world, including but not limited to the Imperial College of London and Johns Hopkins University.

The Company is also capable of supporting commercial research institutions with product donations, including charitable contributions to provide its purified extracts and formulations to end-of-life distressed patients. The announcement comes on the heels of a recent landmark decision by Health Canada to permit four terminally ill patients to consume psilocybin mushrooms to ease their distress. This historic decision establishes a precedent that will pave the way for a wider adoption of psilocybin-based therapies.

“Mydecine’s breakthrough to legally supply naturally-sourced psilocybin within our spore-to-sale™ process will be a major advancement for mental therapeutics, due to the fact that these unique psychedelic compounds are both safe and effective for afflictions, such as depression, anxiety, and PTSD,” quoted Damon Michaels, COO and Co-Founder of Mydecine™.

There is still debate as to which is more successful in psychedelic-based treatments between naturally derived psilocybin or the use of a synthetic form. Given Mydecine’s full legal ability to access both types of active compounds, the Company is poised to internally answer that question as well as aid various qualified groups also conducting this type of research. In theory, there are a plethora of added benefits in regard to the entourage effect(₂) of naturally-sourced psilocybin versus the synthetic route. Additionally, Mydecine™ is developing a number of unique API’s(₃) from their naturally-sourced cGMP psychedelic extracts. Mydecine™ will also be conducting R&D to produce novel proprietary formulations by synergizing psychedelic fungi compounds with other various API’s; Mydecine™ will then attach their formulations to their exclusive delivery mechanisms. Mydecine™ plans to utilize these psychedelic medicinal formulations in various clinical environments around the world in aspiration to better the lives of many.

The Company notes that although several international companies and research institutions are permitted to utilize synthesized psilocybin, the process is extremely challenging and cost prohibitive(₄) with a single gram having the price tag of thousands of dollars. Being able to legally extract psilocybin from its natural source, Mydecine™ will hope to reduce these significant costs and improve the scalability of world-class research initiatives and novel therapies.

CEO and Director of Mydecine™, Joshua Bartch stated, “We are extremely grateful to have the ability to provide cGMP psychedelic API’s to qualified organizations, research partners, nonprofits, and clinical groups throughout the globe. We believe the reason current psilocybin-based research initiatives come with a very high cost using inefficiently produced synthetic psilocybin is simply due to a lack of capabilities and legal restraints. Mydecine’s legal capabilities through the dealer’s license will incorporate our range of abilities, which will be valuable for naturally-sourced medicine paired with new-age technology. We believe our achievement is the first-of-its-kind.”

1 Current Good Manufacturing Practices. GMP is a system for ensuring that products are consistently produced and controlled according to the best quality standards.

2The“entourage effect” is a proposed mechanism by which active compounds act synergistically to modulate the overall effects of multiple active compounds working together to produce a polypharmaceutical medicine.

3Active Pharmaceutical Ingredient/s are single or poly ingredients in pharmaceutical medicines that are biologically active.

4 Current synthesized psilocybin applied to recent psychedelic research sells for ~$7-10k USD per gram.

 

About Mydecine Innovations Group Inc.
Mydecine Innovations Group™is a publicly traded life sciences parent company with offices in Denver, CO and Vancouver, BC. Mydecine™ is dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development, including synthesis, genetic research, import/export, delivery system design, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company.Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including,without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.


StaffJuly 24, 2020
p04gk42r-scaled.jpg?fit=1200%2C675&ssl=1

7min12520

As the psychedelics and functional mushrooms industry continues to carve out its own space in today’s world, we continue to see massive talent move into the highest positions available. Similar to where cannabis was just a few years ago.  Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”) announced that they have hired former Red Bull marketing executive, Jim Gunning, as the Company’s new Chief Marketing Officer (“CMO”). Gunning told Green Market Report that his strategy is to implement a program that will boost overall industry recognition. 

“When I was first contacted by Damon Michaels, the company’s Chief Operations Officer, regarding the high-level plans for Mydecine Innovations Group, I could hardly believe what I was hearing,” said Gunning. “He mentioned they had assembled an incredibly talented forward-thinking team, but even more so, they had already developed such a unique and strong vision on how they wanted to approach and establish themselves which really aligned with my thoughts of what it would take to be a leader in the mycology space. It is such an honor accepting a key role to bring the Mydecine vision to life.”

With more than two decades of experience in the world of marketing, Gunning is a master of developing sales and marketing strategies for Fortune 500 companies. As one of the original employees at Red Bull North America™, Gunning played a critical role as Sports Marketing Director for 10 years straight, developing the company from a small start-up to a global brand with sales generating hundreds of millions of dollars annually in North America alone; working closely with the Red Bull’s domestic and global sales and marketing teams to maximize all activation opportunities throughout the organization, including PR, Content, Collegiate, Culture, Events, Trade and Online Interactive departments while managing a multi-million dollar marketing budget.

Gunning has also served as the Managing Director of RESQWATER™, a post workout recovery beverage designed to replenish nutrients and flush toxins, where he has helped guide the brand to exceed target goals in its sales and marketing program.  Most recently, Gunning has served as a consultant for the hemp-derived cannabinoid company called Blue Sky Biologicals to manage a plethora of product SKUs under Blue Sky’s brand, KANABIA™, where he was responsible for overseeing and developing all strategic marketing initiatives. 

In his new role as CMO, Gunning will be responsible to help turn Mydecine into a household name and grow it into a stand-alone brand where clients and consumers can develop engagement, trust, and loyalty through engaging programs that deliver value propositions in mental health and wellness solutions utilizing the vast options of medicinal fungal compounds. One of Gunning’s initial duties as CMO will be to develop a marketing campaign around Mydecine’s new fungtional™ mushroom product line which should be on retail shelves across the U.S. sometime around Q4 of this year under the operational branch of the Company, Mydecine Health Sciences™.

“I believe in the very near-term future fungi is going to play a far more significant role in our daily lives than we can ever imagine,” added Gunning. “There are so many diverse applications to fungi that are in the classically defined “emerging” category of development; from health and beauty products, to meat alternatives, sustainable packaging, environmental remediation to even fashion.” 

Damon Michaels, COO of Mydecine, stated, “When I first met Jim, sure I was impressed like anyone else would be with his incredible background, especially with my own passion in previous endeavors with action sports, but what else I saw in Jim amounted to much more. Jim’s years of professional experience in marketing, sales, and relationship building easily shine through his work ethic and his genuine, relaxed and humble personality are obvious seasoned traits you would only find in someone that is truly confident with the incredible skills and talents that Jim has acquired. I believe that it was very fortunate for Jim and I to cross paths in this world and I knew from the beginning that we would one day do great things together. I am very happy to welcome Jim into the Company and add him to our amazing dynamic team.” 

Further, the Company announces the resignation of Mr. Benjamin Martch as Chief Marketing Officer and from the Board of Directors. The Company would like to thank Ben for his time, services, and for the valuable contributions he made during his tenure as CMO and as a director.

Ben will be transitioning to an executive role within the Company’s 50% owned distribution company, Levee Street Holdings LLC, to continue his focus and passion building out Levee Street’s distribution network with Greg Kassanoff (Levee Street’s CEO) and the rest of the Levee Street team. Through Levee Street, Ben will also be supporting the growth of various hemp-derived cannabinoid brands as the Company continues to grow its revenue and product offerings.

 


StaffJuly 21, 2020
shutterstock_533369773-scaled.jpg?fit=1200%2C700&ssl=1

4min9270

Today Mydecine Innovations Group Inc. (CSE: MYCO) (OTCMKTS: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”) announced that its subsidiary Mindleap Health Inc. ( “Mindleap” )  signed an agreement with Brightmind (“Brightmind”) to launch a comprehensive meditation program on Mindleap’s advanced digital health platform.

Brightmind is a leading meditation app that provides customized and practical instruction by world-class meditation experts. Brightmind offers a robust curriculum that is based on an approach to teaching developed over the past 40 years by the esteemed meditation educator Shinzen Young.

Under the terms of the agreement Brightmind will provide specialized meditation content to Mindleap and Mindleap will make that content available for purchase on the platform.

Brightmind is the first and only app that makes Shinzen’s powerful system easily available. The Brightmind app has been downloaded over 100,000 times and has been featured by Apple in their coveted “New Apps We Love” section, as well as Forbes and Huffington Post. Shinzen’s system is so clear and well organized that neuroscience researchers at Harvard and other top universities use his system to design their experiments and have brought Shinzen on as a research consultant.

“Our vision is for a world where people can make lasting life changes by having advanced tools and access to expert mental health professionals right from the palm of their hand. Mindfulness can have numerous benefits, everything from decreased stress and sadness to increased levels of happiness and focus. Brightmind’s programs have provided radical transformations for thousands of people and the partnership with Mindleap should lead to more value for our customers and platform,” said Mindleap Founder and CEO Nikolai Vassev.

Over the past 20 years, meditation and mindfulness-based programs have become increasingly popular. Doctors and mental health professionals are embracing meditation because scientific studies are beginning to show that it works, particularly for stress-related conditions.

The market for meditation apps has exploded into the mainstream and shows little sign of slowing down. In 2019 alone, the meditation market reached $1.2 Billion (USD). Employers are embracing mindfulness training and leading apps like Headspace and Calm are reaching over 50 million downloads while commanding billion dollar valuations. The major players offer relatively simple and shallow meditation instruction, which their users quickly exhaust while Brightmind’s comprehensive and proven programs offer a much more robust value to end users.

Meditation, when practiced and contextualized well, is one of the most effective methods for improving mental health.

“Meditation is a way to upgrade our mental software to meet the demands of our rapidly changing world. We have been hard at work to deliver exceptional programs and are thrilled to collaborate with Mindleap so we can deliver our programs to even more people,” said Brightmind Founder and CEO Toby Sola.

The Brightmind Meditation program will be a part of five other digital health programs that will be offered on Mindleap later this fall. The scalability, consistency, and reduced costs to end users create more comprehensive and versatile offering for the Mindleap platform.


AxisWireJuly 21, 2020
logo_mydecine.png?fit=850%2C531&ssl=1

7min7960

Vancouver – July 21, 2020 /AxisWire/ Mydecine Innovations Group Inc. (CSE: MYCO) (OTCMKTS: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health Inc. ( “Mindleap” ) has signed an agreement dated July xx, 2020  with Brightmind (“Brightmind”) to launch a comprehensive meditation program on Mindleap’s advanced digital health platform. Under the terms of the agreement Brightmind will provide specialised meditation content to Mindleap and Mindleap will make that content available for purchase on the platform. 

Brightmind is a leading meditation app that provides customized and practical instruction by world-class meditation experts. Brightmind offers a robust curriculum that is based on an approach to teaching developed over the past 40 years by the esteemed meditation educator Shinzen Young

Brightmind is the first and only app that makes Shinzen’s powerful system easily available. The Brightmind app has been downloaded over 100,000 times and has been featured by Apple in their coveted “New Apps We Love” section, as well as Forbes and Huffington Post. Shinzen’s system is so clear and well organized that neuroscience researchers at Harvard and other top universities use his system to design their experiments and have brought Shinzen on as a research consultant.

Mindleap Founder and CEO Nikolai Vassev commented: “Our vision is for a world where people can make lasting life changes by having advanced tools and access to expert mental health professionals right from the palm of their hand. Mindfulness can have numerous benefits, everything from decreased stress and sadness to increased levels of happiness and focus. Brightmind’s programs have provided radical transformations for thousands of people and the partnership with Mindleap should lead to more value for our customers and platform. 

Over the past 20 years, meditation and mindfulness-based programs have become increasingly popular. Doctors and mental health professionals are embracing meditation because scientific studies are beginning to show that it works, particularly for stress-related conditions. 

The market for meditation apps has exploded into the mainstream and shows little sign of slowing down. In 2019 alone, the meditation market reached $1.2 Billion (USD). Employers are embracing mindfulness training and leading apps like Headspace and Calm are reaching over 50 million downloads while commanding billion dollar valuations. The major players offer relatively simple and shallow meditation instruction, which their users quickly exhaust while Brightmind’s comprehensive and proven programs offer a much more robust value to end users.  

Meditation, when practiced and contextualized well, is one of the most effective methods for improving mental health. 

Brightmind Founder and CEO Toby Sola commented: “Meditation is a way to upgrade our mental software to meet the demands of our rapidly changing world. We have been hard at work to deliver exceptional programs and are thrilled to collaborate with Mindleap so we can deliver our programs to even more people.” 

The Brightmind Meditation program will be a part of five other digital health programs that will be offered on Mindleap later this fall. The scalability, consistency, and reduced costs to end users create more comprehensive and versatile offering for the Mindleap platform. 

About Mydecine Innovations Group 

Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions. Mydecine’s experienced cross functional dynamic team has the capability to oversee all areas of drug development including synthesis, drug delivery system development, clinical trial execution, through to product commercialization and marketing. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations Mydecine is at the forefront of the efficient development of psychedelic derived medicines and therapeutic solutions. Our trailblazing portfolio of companies is focused on providing innovative and effective treatment options that can help millions of people live healthier lives.

About Mindleap Health 

Mindleap is developing an advanced digital health platform that will provide support for people that are looking to achieve personal transformations and overcome mental health challenges. Mindleap is the only digital health platform that combines telehealth with mood, emotion and habit tracking. This is a paradigm shift to conventional mental health as Mindleap personalized support and users have the tools needed to track their progress and take control of their mental health.   

Learn about Mindleap Health 

About Brightmind 

Brightmind is a leading meditation application that presents a unique approach to meditation that users describe as comprehensive, precise, and practical. Brightmind helps people deepen their practice, learn how to meditate while doing daily activities and use meditation to fuel a positive vision for their lives. 

Download Brightmind today for free on the App Store or Google Play store.

 


Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 11 hours

New Report from ⁦@headset_io⁩ Says Medical Cannabis Consumers Spend More. New story from ⁦@julsaitch⁩

@GreenMarketRpt – 11 hours

Yowza. Be careful when investing in crowdfunding deals. SEC files complaint against CEO and others for…

Back to Top